In our previous paper we have documented a different expression of soluble HLA (Human leukocyte antigen)-G molecules between Ulcerative Colitis (UC) and Crohn’s Disease (CD) patients confirming the presence of different biological characteristics. We have observed a spontaneous secretion in peripheral blood mononuclear cell (PBMC) cultures of CD patients but not in those of UC patients. Moreover, a lack of sHLA-G antigens has been reported in UC patient cultures after lipopolysaccharide (LPS) activation. Our new results suggest that the therapy is able to normalize the production of HLA-G molecules in both CD and UC patients but in a different way: immunosuppressant therapy decreases the hyper-production of HLA-G in CD patients while it starts the release of HLA-G in UC patients. These data confirm the diversity in the behaviour of these two pathologies and propose the analysis of sHLA-G levels in CD and UC patients during the therapeutic follow-up with the goal to distinguish between UC and CD patients and to monitor the therapy. If these results are confirmed in a prospective study, HLA-G could be considered a plasmatic biomarker to establish an individualized treatment to control inflammation, to reduce symptoms and to maintain remissions in inflammatory bowel diseases.

Therapy modifies HLA-G secretion differently in Crohn's disease and ulcerative colitis patients.

ZELANTE, Angelo;GULLINI, Sergio;BARICORDI, Olavio;RIZZO, Roberta
2011

Abstract

In our previous paper we have documented a different expression of soluble HLA (Human leukocyte antigen)-G molecules between Ulcerative Colitis (UC) and Crohn’s Disease (CD) patients confirming the presence of different biological characteristics. We have observed a spontaneous secretion in peripheral blood mononuclear cell (PBMC) cultures of CD patients but not in those of UC patients. Moreover, a lack of sHLA-G antigens has been reported in UC patient cultures after lipopolysaccharide (LPS) activation. Our new results suggest that the therapy is able to normalize the production of HLA-G molecules in both CD and UC patients but in a different way: immunosuppressant therapy decreases the hyper-production of HLA-G in CD patients while it starts the release of HLA-G in UC patients. These data confirm the diversity in the behaviour of these two pathologies and propose the analysis of sHLA-G levels in CD and UC patients during the therapeutic follow-up with the goal to distinguish between UC and CD patients and to monitor the therapy. If these results are confirmed in a prospective study, HLA-G could be considered a plasmatic biomarker to establish an individualized treatment to control inflammation, to reduce symptoms and to maintain remissions in inflammatory bowel diseases.
2011
Zelante, Angelo; R., Borgoni; C., Galuppi; V., Cifalà; L., Melchiorri; Gullini, Sergio; Baricordi, Olavio; Rizzo, Roberta
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/1460116
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact